Compare RBBN & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | RGNX |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.1M | 661.2M |
| IPO Year | 2000 | 2015 |
| Metric | RBBN | RGNX |
|---|---|---|
| Price | $2.95 | $14.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $6.00 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 737.2K | 626.9K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $868,592,000.00 | $161,318,000.00 |
| Revenue This Year | $5.02 | $132.80 |
| Revenue Next Year | $5.74 | $48.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.38 | ★ 91.30 |
| 52 Week Low | $2.72 | $5.04 |
| 52 Week High | $5.38 | $14.24 |
| Indicator | RBBN | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 65.59 |
| Support Level | $2.73 | $12.69 |
| Resistance Level | $3.05 | $13.42 |
| Average True Range (ATR) | 0.09 | 0.84 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 67.19 | 74.65 |
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.